CSE PREV
LAST 0.025
CHANGE 0.000
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.025
CHANGE: 0.000
OTC: PRVCF
FSE: 18H

Investors

News Releases

  • 2024
  • 2023
  • 2022
  • 2021
  • Archive
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
Dec 18, 2024
PreveCeutical Announces Change of Auditors
Dec 9, 2024
BioGene Therapeutics Appoints Patroski J. Lawson to Board of Directors
Dec 5, 2024
BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho
Dec 4, 2024
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
Dec 2, 2024
BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors
Nov 25, 2024
BioGene Therapeutics Welcomes Dr. Deepak Sampath, PhD. to Its Board of Directors
Nov 21, 2024
BioGene Therapeutics Welcomes Professor Mirela Delibegovic, FRSE to Its Scientific Advisory Board
Nov 18, 2024
PreveCeutical’s subsidary, BioGene Therapeutics Announces Strategic Appointments: Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer
Nov 15, 2024
PreveCeutical Announces Closing of BioGene Therapeutics Transaction
Nov 13, 2024
PreveCeutical’s subsidiary, BioGene Therapeutics, appoints President
Oct 30, 2024
PreveCeutical Launches Strategic Partnership with BioGene Therapeutics
Oct 18, 2024
PreveCeutical Engages Phoenix Corporate Finance Inc. to Provide Advisory Services
Sep 3, 2024
PreveCeutical Engages Outside The Box Capital Inc. to Provide Marketing Services
Jul 9, 2024
PreveCeutical Announces Revocation of Management Cease Trade Order
Jun 28, 2024
PreveCeutical Provides Update on Management Cease Trade Order
Jun 17, 2024
PreveCeutical Enters Into Loan Agreement
Jun 6, 2024
PreveCeutical Commences Litigation Against Former Legal Counsel in the British Columbia Supreme Court Alleging Professional Negligence
May 30, 2024
PreveCeutical Provides Update on Management Cease Trade Order
May 29, 2024
PreveCeutical Announces First Tranche Closing of Private Placement
May 16, 2024
PreveCeutical Provides Update on Management Cease Trade Order
May 2, 2024
PreveCeutical Annouces Management Cease Trade Order
Dec 4, 2023
PreveCeutical Initiates Preparation of Proof-of-Concept Preclinical Study for its Diabetes & Obesity Dual Gene Therapy Program
Sep 18, 2023
PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application
Sep 12, 2023
PreveCeutical Showcases Dynamic Evolution in AI Strategy
Aug 31, 2023
PreveCeutical Engages New to the Street for Production & Broadcasting Services
Jul 24, 2023
PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia
Jun 28, 2023
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation And Antiviral Use & Cyclic Peptides And Uses Thereof
May 30, 2023
PreveCeutical Medical – Sol-Gel and Uses thereof Patent Update
Apr 24, 2023
PreveCeutical Medical Launches Clinical Artificial Intelligence Division
Apr 20, 2023
PreveCeutical Medical Announces Live Interactive Q&A Video Conference
Apr 4, 2023
PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
Mar 20, 2023
PreveCeutical Initiates Non-Addictive Analgesic (Painkiller) Program Clinical Development Program & Disclosure Committee
Mar 6, 2023
PreveCeutical – International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
Feb 21, 2023
Appointment of C. Evan Ballantyne to PreveCeutical’s Board of Directors
Feb 7, 2023
PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
Jan 25, 2023
PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
Jan 23, 2023
PreveCeutical – Background IP, US Patent Granted Disulfide Bond Containing Compounds
Jan 17, 2023
PreveCeutical – Dynorphin Peptides (Painkiller) and Uses thereof Patent Update and Officer Update
Jan 12, 2023
PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
Jan 9, 2023
PreveCeutical signs Intercompany Sol-Gel License Agreement
Nov 21, 2022
PreveCeutical files Application for D-amino Acid Peptides
Nov 11, 2022
PreveCeutical Announces Conversion of Debt
Oct 20, 2022
Appointment of Kathleen Rokita to PreveCeutical’s Board of Directors
Sep 16, 2022
PreveCeutical Announces Resignation of Board of Director Member
Sep 6, 2022
Appointment of Sachin Nanavati to PreveCeutical’s Board of Directors
Jul 22, 2022
PreveCeutical Enters into Credit Facility Agreement
May 27, 2022
PreveCeutical Announces Change in Directors and Investor Awareness Services
May 9, 2022
Article based on PreveCeutical’s Pain Management Peptides Program published in the British Journal of Pharmacology
Mar 30, 2022
PreveCeutical Announces Debt Settlement and Conversion of Debt
Jan 13, 2022
Settlement Reached in Tietz Class Action Lawsuit
Nov 29, 2021
PreveCeutical files International Patent Application for Sol-Gel Cannabinoid Formulation for Antiviral Use
Nov 24, 2021
PreveCeutical files Provisional Patent Application for D-Amino Acid Peptides
Nov 18, 2021
PreveCeutical Signs License Agreement for Exclusive Rights to Use UniQuest’s Sol-Gel Technology for Delivery of Cannabinoids
Oct 5, 2021
Caroline MacCallum, MD, FRCPC, BSc Pharm, Joins PreveCeutical
Aug 31, 2021
PreveCeutical Receives AU$315,338 Research & Development Tax Incentive Cash Refund
Jul 7, 2021
PreveCeutical files International Patent Application for its Dynorphin Peptides
May 31, 2021
PreveCeutical Provides Corporate Update
Mar 15, 2021
PreveCeutical Appoints Founding Director of RAS Life Science Solutions Aditya Bahl as Advisor
Mar 12, 2021
PreveCeutical Announces Debt Settlement and Conversion of Debt
Feb 23, 2021
Accomplished Biophysicist Linnéa Olofsson, Ph.D. Joins PreveCeutical
Feb 2, 2021
PreveCeutical Announces Completion of Pain Management Peptides Program
Jan 5, 2021
PreveCeutical files Provisional Patent Application for its BSV Peptide
Nov 25, 2020
Successful Completion of the COVID-19 Sol-Gel Formulation Development
Nov 23, 2020
PreveCeutical Files Provisional Patent Application for its COVID-19 Formulation
Nov 10, 2020
PreveCeutical Provides Update on its COVID-19 Cannabinoid Sol-Gel Program
Oct 29, 2020
PreveCeutical Receives Extension of Six Months to Hold its Annual General Meeting from the Registrar of Companies, British Columbia
Oct 9, 2020
PreveCeutical’s Application For COVID-19 Therapy Funding Update
Oct 1, 2020
Veteran Johnson & Johnson Executive Dr. Ajit Shetty Joins PreveCeutical
Sep 8, 2020
PreveCeutical Provides Lead Pain Management Peptides Update
Sep 2, 2020
PreveCeutical Announces Lead Pain Management Peptides Identified for Preclinical Evaluation
Aug 31, 2020
PreveCeutical Files an Application for a Provisional Patent for Sol-gel Cannabinoids
Aug 17, 2020
PreveCeutical Receives AU$1,227,902 Research & Development Tax Incentive Cash Refund
Aug 4, 2020
PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program
Jul 30, 2020
PreveCeutical Announces Appointment of Director and Public Officer
Jul 21, 2020
PreveCeutical Approaches Completion of Non-Addictive Analgesic Program
Jul 15, 2020
PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity
Jul 13, 2020
PreveCeutical Confirms Receipt of CBD For Sol-Gel
Jul 8, 2020
PreveCeutical Announces Filing of Provisional Patent Application
Jul 6, 2020
PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program
Jun 29, 2020
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes & Obesity
Jun 22, 2020
PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as A Potential Treatment for SARS-CoV-2 Infection
Jun 17, 2020
PreveCeutical Announces Sol-Gel Chemistry Fingerprinting SOPs
Jun 16, 2020
PreveCeutical Issued Statement Regarding Promotional Activity
Jun 15, 2020
PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report
Jun 8, 2020
PreveCeutical Announces Certain Warrants Expiring on June 29, 2020
Jun 3, 2020
PreveCeutical Announces Successful Completion of its Sol-gel Program
Jun 1, 2020
PreveCeutical Applies for Viral Prevention Program Funding
May 22, 2020
PreveCeutical Announces Debt Settlement and Conversion of Debt
May 4, 2020
PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-Gel
Apr 29, 2020
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller
Feb 24, 2020
PreveCeutical Announces Patent Cooperation Treaty (“PCT”) Application
Jan 23, 2020
PreveCeutical Retains Patent Legal Team
Jan 14, 2020
PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
Jan 8, 2020
PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue
Oct 29, 2019
PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Oct 7, 2019
PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
Sep 23, 2019
PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
Sep 3, 2019
PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics
Aug 6, 2019
PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property
Jul 19, 2019
PreveCeutical Named in Lawsuit
Jul 9, 2019
PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System
Jun 21, 2019
PreveCeutical Announces Appointment of New Directors
Jun 17, 2019
PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program
Jun 3, 2019
PreveCeutical Secures $300,000 Loan and Resignation of a Director
May 21, 2019
PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program
Apr 26, 2019
PreveCeutical's Chief Research Officer, Dr. Harry Parekh joined Steve Darling from Proactive Investors to talk about the companies progress in the development of their Sol-gel Program.
Apr 17, 2019
PreveCeutical Partnership Leads to Two New Patent Filings
Apr 15, 2019
PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program
Apr 10, 2019
PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Apr 8, 2019
PreveCeutical Announces Default Judgment Against JCN Capital Corp.
Apr 4, 2019
Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project
Mar 25, 2019
PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.
Mar 11, 2019
PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Feb 13, 2019
PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President
Feb 12, 2019
PreveCeutical Announces Closing of Non-Brokered Private Placement
Jan 29, 2019
PreveCeutical to Explore Partnerships with Pharmaceutical and Biotechnology Companies for the Co-Development of its Sol-Gel System
Jan 14, 2019
PreveCeutical Provides Update on the Dual Gene Therapy Program
Jan 8, 2019
PreveCeutical Provides Update on Research Program for Development of Non-Addictive Analgesics
Jan 7, 2019
PreveCeutical Files Notice of Civil Claim Against the BridgeMark Group
Dec 19, 2018
PreveCeutical Provides Year End Corporate Update
Nov 28, 2018
PreveCeutical Responds to British Columbia Securities Commission
Nov 20, 2018
PreveCeutical Converts Acidic Phytocannabinoids to Neutral Form and Doubles Contents of Fingerprinted Cannabis Extract Library
Nov 19, 2018
PreveCeutical Confirms Encouraging Results from Sol-gel Applicator Trials for Achieving Direct Nose-to-Brain Delivery in an Adult Human Nasal Cast
Nov 13, 2018
PreveCeutical Announces LOI with Crushedit LLC to Supply CBD Isolate for Expected Sale Proceeds of $16.25 Million
Nov 5, 2018
PreveCeutical Applies its Proprietary Extraction Protocol for Medical Cannabinoids to Two Additional Cannabis Strains
Oct 31, 2018
PreveCeutical Provides Update on Visit to Penta 5 Group’s Facility for Due Diligence on Proposed Acquisition
Oct 30, 2018
PreveCeutical Holds Intensive Workshop to Advance Dual Gene Therapy Research Program for Type 2 Diabetes and Obesity
Oct 15, 2018
PreveCeutical to Visit Penta 5 Group’s Packaging Facility for Due Diligence on Proposed Acquisition
Oct 3, 2018
PreveCeutical Announces LOI to Acquire Penta 5 Health and Wellness Packaging Companies with Market-Ready Products and Production Facilities
Sep 28, 2018
PreveCeutical Engages Invictus Resources to Provide Investor Awareness Services
Sep 26, 2018
PreveCeutical Enters into Development Agreement with Asterion Cannabis Inc. to Develop Medicinal Cannabinoid Products
Sep 18, 2018
PreveCeutical Confirms No Material Change
Sep 4, 2018
PreveCeutical Develops Proprietary Extraction Protocol for Medical Cannabinoids to be Used with the Sol-gel Drug Delivery Program
Aug 22, 2018
PreveCeutical Provides Corporate Update
Aug 15, 2018
PreveCeutical Signs Agreement with Asterion Cannabis Inc. to License Natural Health Products and Engages Monster Media, LLC to Provide Investor Relations Services
Aug 8, 2018
PreveCeutical Announces First Cannabis Product for Treatment of Anxiety
Jul 31, 2018
PreveCeutical Provides Update on Second Phase of Scorpion Venom-Derived Peptide Program
Jul 24, 2018
PreveCeutical Announces Launch of Cannabis Division
Jul 11, 2018
PreveCeutical Provides Update on Sol-gel Drug Delivery Program
Jul 10, 2018
PreveCeutical Retains Link Media LLC to Provide Marketing Services
Jun 29, 2018
PreveCeutical Announces the Closing of Oversubscribed Non-Brokered Private Placement
Jun 25, 2018
PreveCeutical Announces Oversubscribed Non-Brokered Private Placement
Jun 8, 2018
PreveCeutical Amends Terms of Warrants to Extend Expiry Date
Jun 5, 2018
PreveCeutical Engages Stadnyk & Partners to Provide Market Awareness and Strategic Advisory Services
May 23, 2018
PreveCeutical Provides Update on Forward Stock Split
May 17, 2018
PreveCeutical Shareholders Approve Five-for-One Forward Stock Split
May 14, 2018
Second Shipment of Dried Cannabis Materials Arrives at the Pharmacy Australia Centre of Excellence
May 7, 2018
PreveCeutical Signs Non-Disclosure Agreement with World Leading Specialized Drug Delivery Device Manufacturer
May 3, 2018
Second Shipment of Dried Cannabis Materials Shipped to Pharmacy Australia Centre of Excellence by PreveCeutical’s Canadian Licensed Producer Partner for Novel Nose-to-Brain Drug Delivery Research
Apr 27, 2018
PreveCeutical Enters into Credit Facility Agreement Amends Credit Facility Agreement
Apr 9, 2018
PreveCeutical Announces Non-Brokered Private Placement and 2018 Annual General and Special Meeting Date
Mar 29, 2018
Arrival of Aurora’s Cannabis Material at Pharmacy Australia Centre of Excellence
Mar 16, 2018
PreveCeutical - Announces Incorporation of Australian Subsidiary to Support Ongoing Research Programs
Mar 13, 2018
PreveCeutical - Aurora Exports Dried Cannabis Flower and Oils to Australia for Research by PreveCeutical
Feb 26, 2018
PreveCeutical - Appoints Dr. Maher Khaled as Director of International Operations
Jan 30, 2018
PreveCeutical Signs Research and Option Agreement with UniQuest Pty Limited for Development of Non-Addictive Analgesic Peptides
Jan 24, 2018
PreveCeutical - Provides Update on Scorpion Venom-Derived Peptide Program
Jan 15, 2018
PreveCeutical - Now Accepts Bitcoin as a Payment Method
Jan 3, 2018
PreveCeutical - Announces Amendment to $3.28 Million Non-Brokered Private Placement
Nov 22, 2017
PreveCeutical - Announces $3.28 Million Fully Subscribed Private Placement
Nov 1, 2017
PreveCeutical - Receives Australian State Approval to Acquire and Use Cannabis as Part of its R&D Program
Oct 26, 2017
PreveCeutical - Announces Appointment of Dr. Makarand Jawadekar to its Board of Directors
Oct 23, 2017
PreveCeutical - Announces Filing of Amended and Restated Interim Financial Statements
Sep 25, 2017
PreveCeutical - Applies to List on the TSX Venture
Sep 21, 2017
PreveCeutical - Announces Strategic R&D Supply Agreement
Sep 18, 2017
PreveCeutical - Begins Trading on the OTCQB Venture Marketplace
Sep 15, 2017
PreveCeutical - Launches New Corporate Website
Sep 13, 2017
PreveCeutical Engages the Susan Blond Group Inc. for Publicity Services and Appoints Ms. Susan Blond as Director of Publicity
Aug 30, 2017
PreveCeutical - Announces Joint Venture with Sports 1 Marketing for Concussion Therapy
Aug 16, 2017
PreveCeutical - Begins Trading on the OTC Market
Aug 14, 2017
PreveCeutical - Requisitions to Acquire Instrumentation Expediting R&D Programs
Aug 11, 2017
PreveCeutical - Preliminary Results from Phase One of Venom Re-Engineering Project
Aug 8, 2017
PreveCeutical - Letter of Intent Signed with UniQuest Pty Limited
Aug 1, 2017
PreveCeutical - Begins Trading on the Frankfurt Stock Exchange
Jul 25, 2017
PreveCeutical - Launches Phase One of Venom Re-Engineering Project
Jul 17, 2017
PreveCeutical - Signs Research and Option Agreement with UniQuest
Jul 10, 2017
PreveCeutical - Closing of Reverse Take-Over Transaction
Jun 21, 2017
PreveCeutical - Carrara Receives Acquisition Acceptance
May 17, 2017
PreveCeutical - Harendra Parekh Appointed Chief Research Officer
Apr 24, 2017
PreveCeutical - R&D Agreement Signed with UniQuest for CBD Formulations
Apr 20, 2017
PreveCeutical - R&D Agreement Signed With UniQuest Pty Limited
Apr 13, 2017
PreveCeutical - Letter of Intent Signed with UniQuest Pty Limited
Mar 29, 2017
PreveCeutical - Investor Presentation & Private Placement Financing
Mar 24, 2017
Carrara Final Equity Raise
Mar 22, 2017
PreveCeutical - Carrara & PreveCetuical Sign Amalgamation Agreement
Feb 17, 2017
PreveCeutical - Carrara Signs Acquisition Letter of Intent
Dec 20, 2016
PreveCeutical - Scorpion Venom: Assists in Health & Wellness
Oct 5, 2016
PreveCeutical - Filing of Preliminary Prospectus for Initial Public Offering
Sep 6, 2016
PreveCeutical - Appointment of Shabira Rajan CPA-CGA as Chief Financial Officer
Aug 31, 2016
Shareholder & Investor Update - 50c Funding Round
Aug 16, 2016
PreveCeutical - Appointment of Dr. Makarand Jawadekar as Chief Science Officer
Aug 2, 2016
PreveCeutical - AGM - Greg S. Ried & Alex Bayer for Election as Directors
Jul 11, 2016
PreveCeutical - New Website and Corporate Logo
Jun 27, 2016
PreveCeutical - Public Listing Update
Jun 16, 2016
PreveCeutical - Attending Secret Knock at San Diego, California
Jun 9, 2016
PreveCeutical - Attending Cancer Moonshot Summit at Washinton, DC
Jun 1, 2016
PreveCeutical - Announcing Launch of CELLB9TM
Jan 12, 2016
PreveCeutical - Closing of Debt Financing
Sign up for the latest news and updates

Begin typing and press enter.